Healthcare Services

Diabetic Macular Edema (DME) Market Outlook 2026–2030 Exploring New Business Opportunities

April 1, 2026April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Diabetic Macular Edema (DME) Market Expected To Change Between 2026 And 2030?

The diabetic macular edema (dme) market has experienced consistent expansion in recent years. This market is set to increase from $4.88 billion in 2025 to $5.09 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 4.4%. The historical growth of this market is attributable to the increasing incidence of diabetic eye disease, insufficient early detection practices, a rise in vision impairment cases, the reliance on hospital-based ophthalmology care, and the prolonged duration of diabetes.

The market size for diabetic macular edema (dme) is anticipated to demonstrate consistent growth in the coming years, with projections indicating it will reach $6 billion by 2030, progressing at a compound annual growth rate (CAGR) of 4.2%. This expected expansion over the forecast period is attributable to various factors, including advancements in biologic therapies, the broadening of AI-driven eye screening, an increase in specialty eye clinics, rising awareness concerning diabetic eye complications, and an aging diabetic population. Significant trends during this period are foreseen to include the growing uptake of anti-VEGF therapies, increased application of advanced retinal imaging technologies, the expansion of early diagnosis and monitoring programs, a heightened focus on treatments aimed at vision preservation, and the integration of AI-based ophthalmic screening.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21169&type=smp

What Underlying Factors Are Accelerating The Growth Of The Diabetic Macular Edema (DME) Market?

The projected expansion of the diabetic macular edema (DME) market is significantly influenced by the rising incidence of diabetes. This growing prevalence of diabetes stems from various contributing factors, including inactive lifestyles, poor eating patterns, increasing obesity, an aging global population, and inherent genetic predispositions. Diabetes induces diabetic macular edema through its harmful effects on retinal blood vessels, which in turn permits fluid to seep into the macula, culminating in swelling. A notable example highlighting this trend is the report in June 2023 from the Institute for Health Metrics and Evaluation, a US-based public health research institute, which stated that globally, more than half a billion individuals were diagnosed with diabetes. This figure is projected to surge to 1.3 billion people by 2050, more than doubling its current size. Consequently, the expanding occurrence of diabetes is a primary factor fueling the growth of the diabetic macular edema (DME) market.

How Is The Diabetic Macular Edema (DME) Market Structured Across Different Segments?

The diabetic macular edema (dme) market covered in this report is segmented –

1) By Treatment: Anti-VEGF Therapy, Corticosteroids, Laser Therapy, Surgical Intervention

2) By Disease Stage: Early Stage, Moderate Stage, Advanced Stage

3) By Patient Demographics: Adults, Elderly, Children

4) By Route Of Administration: Intravitreal Injection, Topical, Systemic

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Anti-VEGF Therapy: Monoclonal Antibodies, Recombinant Protein-Based Therapies

2) By Corticosteroids: Intravitreal Steroid Injections, Injectable Sustained-Release Corticosteroids

3) By Laser Therapy: Focal Laser Photocoagulation, Panretinal Photocoagulation

4) By Surgical Intervention: Vitrectomy, Membrane Peeling

What Key Developments And Trends Are Impacting The Diabetic Macular Edema (DME) Market?

Leading companies in the diabetic macular edema (DME) market are concentrating on integrating sustained-delivery implant technology, such as refillable ocular implants, to enhance treatment durability, patient compliance, and the efficiency of vision maintenance. Refillable ocular implants are devices that are surgically placed in the eye to continuously release medication over extended periods, thus enabling less frequent dosing, sustained therapeutic exposure, and a reduced treatment burden. For example, in February 2025, F. Hoffmann-La Roche AG, a biotechnology and pharmaceutical company based in Switzerland, obtained approval for Susvimo (ranibizumab 100 mg/mL delivered via the port delivery platform). This refillable ocular implant is designed to treat DME, offering continuous delivery of ranibizumab, refill intervals as infrequent as twice per year, and vision outcomes that are non-inferior when compared with monthly intravitreal injections. Susvimo improves patient adherence, lessens the injection burden, and supports sustained preservation of vision.

Which Major Players Dominate The Diabetic Macular Edema (DME) Market?

Major companies operating in the diabetic macular edema (dme) market are Roche Holding AG, Bayer AG, Novartis AG, Regeneron Pharmaceuticals, Carl Zeiss Meditec AG, Bausch & Lomb, Carl Zeiss AG, Topcon Corporation, Optos plc, Allergan plc, Chengdu Kanghong Pharmaceutical Group, Kodiak Sciences, Opthea Limited, Oxurion NV, Aerie Pharmaceuticals Inc, Coherus BioSciences, KalVista Pharmaceuticals Inc, Araim Pharmaceuticals Inc, Acucela Inc, Antisense Therapeutics Limited, BCN Peptides SA, Ampio Pharmaceuticals Inc, Oculis SA, ThromboGenics NV, EyePoint Pharmaceuticals Inc.

Read the full diabetic macular edema (dme) market report here:

https://www.thebusinessresearchcompany.com/report/diabetic-macular-edema-dme-global-market-report

Which Region Is Projected To Dominate The Diabetic Macular Edema (DME) Market During The Forecast Period?

North America was the largest region in the diabetic macular edema (DME) market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic macular edema (dme) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Diabetic Macular Edema (DME) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21169&type=smp

Browse Through More Reports Similar to the Global Diabetic Macular Edema (DME) Market 2026, By The Business Research Company

Diabetic Retinopathy Global Market Report

https://www.thebusinessresearchcompany.com/report/diabetic-retinopathy-global-market-report

Non Proliferative Diabetic Retinopathy Global Market Report

https://www.thebusinessresearchcompany.com/report/non-proliferative-diabetic-retinopathy-global-market-report

Macular Degeneration Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/macular-degeneration-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795